Source: Viemed Healthcare Inc.
  • Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq
  • Viemed may repurchase up to 1,984,014 common shares
  • Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq
  • Shares purchased by the company will be cancelled and returned to treasury
  • Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States
  • Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share

Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq.

Under the share repurchase program, Viemed may repurchase up to 1,984,014 common shares ‎representing approximately 5 per cent of the total issued and outstanding common shares as of March ‎4‎, 2022.‎

Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq for the four calendar weeks preceding the date of purchase.

“Based on the strength of our balance sheet and excess free cash flow, we believe we are well positioned to execute on this attractive opportunity to increase shareholder value while maintaining resources to fund our operations and continued growth,” said Casey Hoyt, Viemed CEO.

“This program demonstrates our confidence in the Viemed business and our commitment to creating long term sustainable value for our shareholders.”

All shares will be purchased through the facilities of Nasdaq. The company may discontinue its purchases at any time.‎ Shares purchased by the company will be cancelled and returned to treasury.

Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States.

Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.